Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD

Blood (2019) 134 (Supplement_1): 1958.

https://doi.org/10.1182/blood-2019-128838

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Dale Ludwig, PhD BS, Ruth Bryan, Wojciech Dawicki, PhD, Eileen M Geoghegan, Qing Liang, PhD, Sandesh Seth, MS, MBA, Mamata Gokhale, Mark S. Berger, MD, Vijay Reddy, MD PhD, Ravendra Garg, Kevin Allen, PhD, Ekaterina Dadachova

Blood (2019) 134 (Supplement_1): 5601.

https://doi.org/10.1182/blood-2019-128678

Published: 2019

Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2018-99-111914

Published: 2018

Journal Articles

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Damian J. Green, Shyril O’Steen, Yukang Lin, Melissa L. Comstock, Aimee L. Kenoyer, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Margaret Nartea, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Kelly D. Orcutt, K. Dane Wittrup, Oliver W. Press

Blood (2018) 131 (6): 611–620.

https://doi.org/10.1182/blood-2017-09-807610

Published: 2018

Includes: Supplemental data

Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Blood (2017) 130 (Supplement 1): 2769.

https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769

Published: 2017

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Issa F. Khouri, MD, Bill Erwin, MS, Alison M Gulbis, PharmD, Francesco Turturro, MD, S Cheenu Kappadath, PhD, Dustin Gress, MS, Rosamar B Valverde, Elias J. Jabbour, MD, Roland L Bassett, Jr., Aaron Jessop, MBA,MD

Blood (2016) 128 (22): 662.

https://doi.org/10.1182/blood.V128.22.662.662

Published: 2016

Journal Articles

Desaturation Is Related to the Presence of Dense Red Blood Cells in Sickle Cell Patients and Is Reversed By Hydroxyurea

Gaetana Di Liberto, Laurent Kiger, Michael Marden, Laurent Boyer, Marc Conti, Anoosha Habibi, Marie Georgine Rakotoson, Sanam Khorgami, Benoit Vingert, Bernard Maitre, Frédéric Galacteros, France Noizat-Pirenne, Pablo Bartolucci

Blood (2014) 124 (21): 2713.

https://doi.org/10.1182/blood.V124.21.2713.2713

Published: 2014

Journal Articles

Comparison of Oxidant Stress and Damage-Related Responses after Total Body Irradiation Versus Total Marrow Irradiation in Rodents

Susanta Hui, Yutaka Takahashi, Shernan G. Holtan, MD, Rezvan Azimi, Masashi Yagi, Jessie Ingvalson, Davis Seelig, Parham Alaei, Luke Arentsen, Lindsey Godin, Alex Domek, Michael Ehrhardt, Angela Panoskaltsis-Mortari, PhD

Blood (2014) 124 (21): 3804.

https://doi.org/10.1182/blood.V124.21.3804.3804

Published: 2014

Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2014) 124 (21): 3708.

https://doi.org/10.1182/blood.V124.21.3708.3708

Published: 2014

Journal Articles

Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 ( 211 At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model

Sofia H.L. Frost, PhD, Erlinda B. Santos, BS, Brian W. Miller, PhD, Tom A. Bäck, PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Aimee L. Kenoyer, BS, Shani L. Frayo, BS, Oliver W. Press, MD, PhD, Rainer Storb, MD, Brenda M. Sandmaier, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 5139.

https://doi.org/10.1182/blood.V122.21.5139.5139

Published: 2013

Journal Articles

Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT

Sebastian Giebel, MD, Leszek Miszczyk, MD, PhD, Krzysztof Slosarek, PhD, Leila Moukhtari, Fabio Ciceri, MD, Jordi Esteve, MD, PhD, Norbert Claude Gorin, MD, Myriam Labopin, MD, Arnon Nagler, MD, MSc, Christoph Schmid, MD, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 4565.

https://doi.org/10.1182/blood.V122.21.4565.4565

Published: 2013

Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 3680.

https://doi.org/10.1182/blood.V120.21.3680.3680

Published: 2012

Journal Articles

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Kathleen Schwarz, MD, Wagner Julia, MD, Susanne Schreiber, MD, Burkhard Schmidt, MD, Alexander Hoellein, MD, Mareike Verbeek, MD, Markus Schwaiger, MD, Christian Peschel, MD, Klemens Scheidhauer, MD, Christoph von Schilling, MD, Ulrich Keller, MD

Blood (2012) 120 (21): 3700.

https://doi.org/10.1182/blood.V120.21.3700.3700

Published: 2012

Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD

Blood (2011) 118 (21): 1648.

https://doi.org/10.1182/blood.V118.21.1648.1648

Published: 2011

Journal Articles

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Ajay K. Gopal, MD, Ted Gooley, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 663.

https://doi.org/10.1182/blood.V118.21.663.663

Published: 2011

Journal Articles

Anti CD-20 Radioimmunotherapy (RIT) Can Be Safely and Effectively Delivered in a Community-Based Hospital

Ayad Al-Katib, MD, FACP, Mary Mandziara, NP, Susan Szpunar, PhD, Kleanthe Kolizeras, BS, Mary Steigelman, RN, John Kalabat, MD, Zyad Kafri, MD

Blood (2011) 118 (21): 4991.

https://doi.org/10.1182/blood.V118.21.4991.4991

Published: 2011

Journal Articles

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, Amanda Axtman, Shani L. Frayo, BS, Paul J. Morris, Donald K. Hamlin, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Ted Gooley, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 3636.

https://doi.org/10.1182/blood.V118.21.3636.3636

Published: 2011

Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC

Blood (2010) 116 (21): 4916.

https://doi.org/10.1182/blood.V116.21.4916.4916

Published: 2010

NARROW

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Desaturation Is Related to the Presence of Dense Red Blood Cells in Sickle Cell Patients and Is Reversed By Hydroxyurea

Comparison of Oxidant Stress and Damage-Related Responses after Total Body Irradiation Versus Total Marrow Irradiation in Rodents

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 ( 211 At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model

Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Anti CD-20 Radioimmunotherapy (RIT) Can Be Safely and Effectively Delivered in a Community-Based Hospital

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only